Handelsbanken Fonder
BHVN

Handelsbanken Fonder’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Handelsbanken Fonder’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-8,600
Closed -$1.3M – 1651
2022
Q3 		$1.3M Sell
8,600
-56,000
-87% -$8.3M 0.01% 588
2022
Q2 		$9.41M Sell
64,600
-214,000
-77% -$27.3M 0.06% 302
2022
Q1 		$33M Sell
278,600
-8,500
-3% -$1.06M 0.18% 125
2021
Q4 		$39.6M Buy
287,100
+9,500
+3% +$1.21M 0.19% 124
2021
Q3 		$38.6M Sell
277,600
-15,000
-5% -$1.87M 0.2% 113
2021
Q2 		$28.4M Buy
292,600
+25,000
+9% +$2.03M 0.15% 155
2021
Q1 		$18.3M Buy
267,600
+35,000
+15% +$2.83M 0.1% 196
2020
Q4 		$19.9M Sell
232,600
-36,900
-14% -$3.13M 0.12% 173
2020
Q3 		$17.5M Buy
269,500
+25,200
+10% +$1.65M 0.13% 167
2020
Q2 		$17.9M Sell
244,300
-2,700
-1% -$144K 0.15% 140
2020
Q1 		$8.4M Sell
247,000
-10,000
-4% -$457K 0.18% 125
2019
Q4 		$14M Buy
257,000
+25,000
+11% +$1.24M 0.24% 110
2019
Q3 		$9.68M Buy
232,000
+80,000
+53% +$3.38M 0.2% 122
2019
Q2 		$6.66M Buy
+152,000
New +$8.57M 0.12% 153

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Handelsbanken Fonder's BHVN Position: Q4 2022 in Review

Handelsbanken Fonder sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 8,600 shares — an estimated $1.3M sold.

Handelsbanken Fonder first reported a position in BHVN in Q2 2019 and held it in 14 quarters. The position peaked at $39.6M in Q4 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Handelsbanken Fonder reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Handelsbanken Fonder sold 8,600 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $1.3M.
  • Handelsbanken Fonder first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019 and held it in 14 quarters.
  • Handelsbanken Fonder's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $39.6M in Q4 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Handelsbanken Fonder's 13F filing for Q4 2022, filed 7 Feb 2023.